Generalized Anxiety Disorder Clinical Trial
Official title:
Attention Training for Generalized Anxiety Disorder (Attention Training and Relaxation for GAD: Testing the Efficacy of Home-Delivery)
Generalized Anxiety Disorder (GAD) has high prelevance (up to 8.5%; Roy-Byrne & Wagner, 2004) and leads to functional impairment (Wittchen et al., 2002; Ballenger et al., 2001). Researchers have demonstrated a relationship between attention bias to threatening information and GAD. However, this knowledge has not yet been translated into effective treatments. The goal of this project is develop and test a new computerized treatment for Generalized Anxiety Disorder.
Generalized Anxiety Disorder (GAD) is characterized by excessive, uncontrollable worry
(Barlow, et al., 1986) leading to medical over-utilization, poor perceived health, low
ratings of quality of life, and impairment at work resulting in a significant economic and
public health impact (Wittchen et al., 2002; Ballenger et al., 2001). Lifetime prevalence of
GAD is high (5.7%, Kessler, et al, 2005), with even higher estimates in the primary care
setting (8.5%, Roy-Byrne & Wager, 2004). Researchers have established a relationship between
GAD and attention bias to threatening information (Mogg & Bradley 2005). This knowledge,
however, has not been translated into more effective treatments for this disorder. This
five-year, two site proposal aims to test a computerized treatment for GAD in a
double-blind, placebo-controlled study bridging basic attention bias research and treatment
outcome. We present the results from 7 studies demonstrating the efficacy of attention
modification programs (AMP) in ameliorating symptoms of anxiety. Specifically, we report
results from a pilot study of individuals with Generalized Anxiety Disorder (n=24, Dr Amir's
lab), and high worries (n=24, Dr. Schmidt's lab) demonstrating the effectiveness of the
procedures described in this proposal.
In brief, our intervention was effective in: a) changing biased attention, b) reducing
symptoms of GAD, and c) maintaining its effects in up to one year follow-up. This technique
for changing attention bias in GAD can provide a cost-effective and easy to administer
treatment grounded in basic cognitive science that may help reduce suffering in individuals
with anxiety. A larger study would allow us to test the treatment and examine the
generalizability of the intervention to patients with GAD along with comorbid conditions.
Moreover, we will examine the transportability of the intervention by examining the proposed
intervention at two sites. There are currently 10 participants enrolled in the newest phase
of pilot data collection (SDSU 6, FSU 4).
The goal of the current proposal is to extend these findings to a larger group of
individuals with GAD and to examine the generalizability of the results to individuals with
comorbid GAD. In the current proposal we will test two hypotheses:
1. Individuals with GAD completing the AMP will show a larger reduction in their attention
bias to threat compared to the clinical monitoring group
2. Individuals with GAD completing AMP will show a larger reduction in anxiety symptoms
compared to the clinical monitoring group.
3. Individuals with GAD completing AR will show a larger reduction in anxiety symptoms
compared to the clinical monitoring group.
Specifically, in the current proposal directly responds to the NIMH priorities for
evaluating user-friendly interventions and non-traditional delivery methods to increase
access to evidence-based interventions. We will evaluate the efficacy of a 12-week
computer-delivered home-based treatment program for GAD. Treatment will comprise a
combination of two interventions shown to be efficacious in the treatment of GAD. The
Attention Modification Program (AMP) is a computerized program designed to facilitate
attention disengagement from threatening stimuli (Amir et al., 2009). Applied Relaxation
(AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the
physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007).
Following the recommended guidelines of the NIMH Workgroup on Psychosocial Intervention
Development (Hollon et al., 2002), we review evidence suggesting that both treatments are
ideal candidates for the efficient, economical, and widespread transportation of
evidence-based treatments for GAD. This proposal has the potential for a significant public
health impact by evaluating a new method for delivering evidence-based interventions for
hard-to-reach populations through the use of innovative technologies.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |